Novel AARS2 gene mutations encoding mitochondrial alanyl-tRNA synthetase are important in the spectrum of different phenotypes expressed in the nervous system. Leukodystrophy and ovarian failure in females are common phenotypes. Peripheral demyelination is not a recognized aspect of the AARS2 phenotype. A patient with preceding Lyme neuroborreliosis developed progressive leukodystrophy and peripheral demyelinating motor polyneuropathy. Serial magnetic resonance imaging showed progressive inflammatory demyelination extending to the corticospinal tracts. Treatment with a standard of care of antibiotics and immune-modulatory therapy employing intravenous immune globulin was employed. The contribution of neuroborreliosis is not well understood in the expression of the AARS2 phenotype.
Introduction
The AARS2 gene encodes mitochondrial alanyl-tRNA synthetase (mtARSs). Gotz and colleagues [1] identified a homozygous mutation in the AARS2 gene at 6p21.1 in unrelated Finnish female infants with fatal infantile hypertrophic mitochondrial cardiomyopathy and homozygous mutations affecting the editing and catalytic aminoacylation domains of combined oxidative phosphorylation deficiency-8. Dallabona and coworkers [2] described progressive leukoencepha-lopathy among five women with premature ovarian failure and compound heterozygous mutations in the AARS2 gene, which in direct sequencing identified pathogenic biallelic mutations.
Patient Report
An adolescent male developed combined leukodystrophy and peripheral nerve demyelination in association with a novel compound heterozygous mutation in the AARS2 gene. In 2013, a 16-year-old male with normal birth and development noted a rash and high fever. He resided in rural areas endemic for tick borne disease (TBD). Soon afterward he developed symptoms of stiffness, spasticity and incoordination of the legs followed by involvement of the arms. He 
Discussion
Mutation in mtARS is an important cause of a spectrum of different phenotypes affecting the central nervous system (CNS). Among 9 female and 8 male cases of reported AARS2-associated leukoencephalopathy [2]- [7] , the age at onset ranged from 3 to 35 years. Prominent clinical manifestations included cognitive deficits in 15 patients, CST signs in 14 patients, psychiatric and cerebellar signs each in 12 patients, ovarian failure in all 9 females, and epilepsy in 1 patient. Spinal cord MRI was described in only one other patient [7] , and that showed signal abnormality in the cervicothoracic region. Treatment with corticosteroids, azathioprine and mycophenolate mofetil were given to one patient. In none however, was peripheral neuropathy ascertained clinically, electrodiagnostically, or histopathologically, in life or at postmortem examination.
The accuracy of mitochondrial protein synthesis is dependent on the coordinated action of nuclear-encoded mtARSs and the mitochondrial DNA-encoded tRNAs. Whole-exome sequencing shows the importance of the mtARS proteins for mitochondrial pathophysiology, as nearly every nuclear gene for mtARS recognizes a disease gene for mitochondrial disease, and defects in each, are identified in a tissue-specific disease that commonly affects the brain. The contribution of Lyme neuroborreliosis (LNB) to AARS2-associated leukodystrophy and peripheral neuropathy is uncertain. It is useful to consider LNB in two dimensions, anatomic and temporal with the former leading to peripheral neuropathy and encephalomyelitis; and the latter resulting in abrupt and early onset of clinical manifestations and a later indolent progression when untreated.
Most patients with early LNB are seropositive by conventional two-tiered testing at the time of initial clinical presentation, while intrathecal antibody production directed against Borrelia (B.) burgdorferi, with an elevated Lyme index, and is highly specific for CNS involvement. That index may remain elevated for years following successful treatment. Treatment with a standard of care regimen of antibiotics may not halt the progression of subsequent post-infectious Borrelia immunity by activated cerebral microglia and reactive astrocytes in widespread cortical areas [8] . Patients with enhanced immunity or autoimmunity, triggered by B. burgdorferi (https://www.cdc.gov/lyme/postlds/index.html), are candidates for IVIg therapy [9] .
